The interaction potential of herbal medicinal products: A luminescence-based screening platform assessing effects on cytochrome P450 and its use with devil's claw (Harpagophyti radix) preparations

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 3, 2011, Pages 429-438

  Modarai, Maryam ^a   Suter, Andy ^b   Kortenkamp, Andreas ^a   Heinrich, Michael ^a,c  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b Bioforce AG   (Switzerland)

^c SOUTHERN CROSS UNIVERSITY   (Australia)

Author keywords

(herbal) drug safety; CYP interactions; Cytochrome P450 enzymes; Harpagophytum procumbens; PXR (pregnane X receptor)

Indexed keywords

BERGAMOTTIN; CHLOROGENIC ACID; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; HARPAGIDE; HARPAGOPHYTUM PROCUMBENS EXTRACT; HARPAGOSIDE; LUCIFERASE; PREGNANE X RECEPTOR;

ARTICLE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; FLUORESCENCE; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; LUMINESCENCE; PLANT ROOT; REPORTER GENE;

ANIMALS; CATTLE; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG TOXICITY; GLYCOSIDES; HARPAGOPHYTUM; HERB-DRUG INTERACTIONS; LUMINESCENT MEASUREMENTS; PHYTOTHERAPY; PLANT PREPARATIONS; PLANTS, MEDICINAL; PYRANS; RECEPTORS, STEROID; RETINOID X RECEPTORS;

EID: 79952239753     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01235.x     Document Type: Article

References (34)

1. MHRA website: Directive 2004/24/EC of the European Parliament and of the council of 31 March 2004. Available from: http://www.mhra.gov.uk/home/groups/es- herbal/documents/ websiteresources/con009359.pdf (last accessed 16 December 2010).
2. Williamson EM. Drug interactions between herbal and prescription medicines. Drug Saf 2003; 26: 1073-1092.
3. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009; 69: 1777-1798.
4. Modarai M et al. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol 2007; 59: 567-593.
5. Zou L et al. Effects of intrinsic fluorescence and quenching on fluorescence-based screening of natural products. Phytomedicine 2002; 9: 263-267. (Pubitemid 34475561)
6. Cali JJ et al. Luminogenic cytochrome P450 assays. Expert Opin Drug Metab Toxicol 2006; 2: 629-645. (Pubitemid 46118331)
7. Kliewer SA et al. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002; 23: 687-702. (Pubitemid 35191629)
8. Lemaire G et al. A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2D6 induction by pesticides. Biochem Pharmacol 2004; 68: 2347-2358. (Pubitemid 39535107)
9. Modarai M et al. Safety of herbal medicinal products: echinacea and selected alkylamides do not induce CYP3A4 mRNAexpression. eCAM (accessed 4 April 2010, epub ahead of print). DOI: 10.1093/ecam/nep174.
10. Chrubasik S et al. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract Doloteffin in patients with pain in the lower back, knee or hip. Phytomedicine 2002; 9: 181-194. (Pubitemid 34475549)
11. Fiebich BL et al. Inhibition of TNF alpha synthesis in LPS stimulated primary human moncytes by Harpagophytum extract SteiHap 69. Phytomedicine 2001; 8: 28-30. (Pubitemid 32242089)
12. Chrubasik S. Addendum to the ESCOP monograph on Harpagophytum procumbens. Phytomedicine 2004; 11: 691-695.
13. Wegener T. Devil's Claw: from African traditional remedy to modern analgesic and anti-inflammatory. Herbalgram 2000; 50: 47-54.
14. Clarkson C et al. Identification of major and minor constituents of Harpagophytum procumbens using HPLC-SPE-NMR and HPLC/ESIMS/APCIMS. J Nat Prod 2006; 69: 1280-1288. (Pubitemid 44568234)
15. MHRA website: Harpadol - THR 12297/0013. Available from: http://www.mhra.gov.uk/home/groups/par/documents/ websiteresources/con049303.pdf (last accessed 15 December 2010).
16. Unger M, Frank A. Simultaneous determination of the inhibitory potency of six herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004; 18: 2273-2281. (Pubitemid 39297365)
17. Homöopathisches Arzneibuch (HAB). Bestimmung de Troekenrülks. Deutscher Apotheker Verlag Stuttgart and Govi-Verl., Pharmazeut. VerlEschborn. 2005; 2.2.6, p. 4.
18. Council of Europe European (COE) - European Directorate for the Quality of Medicines (EDQM). Devils claw root monograph. Eur Pharmacopoeia 6.2 edition, 2008; 195: 3729-3730.
19. Technical bulletin TB325. P450-GLO assays. 2008. Available from: http://www.promega.com/tbs/tb325/tb325.pdf (accessed 20 April 2010).
20. ueous non-radioactive cell proliferation assay. 2009. Available from: http://www.promega.com/tbs/tb169/tb169.pdf (accessed 20 April 2010).
21. Crespi CL et al. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 1997; 248: 188-190. (Pubitemid 27218241)
22. Yamamoto T et al. Application of microtiter plate assay to evaluate inhibitory effects of various compounds on nine cytochrome P450 isoforms and to estimate their inhibition patterns. Drug Metab Pharmacokinet 2002; 17: 437-448.
23. Zou L et al. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002; 71: 1579-1589. (Pubitemid 34808718)
24. Yin H et al. Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: application in CYP inhibition evaluation. Xenobiotica 2000; 30: 141-154. (Pubitemid 30125115)
25. Dierks EA et al. Amethod for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 2001; 29: 23-29. (Pubitemid 32041675)
26. Weaver R et al. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 2003; 31: 955-966. (Pubitemid 36759067)
27. Eagling VA et al. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 1998; 45: 107-114. (Pubitemid 28045676)
28. He K et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998; 11: 252-259. (Pubitemid 28194348)
29. Girennavar B et al. Furocoumarins from grapefruit juice and their effects on human CYP3A4 and CYP1B1 isoenzymes. Bioorg Med Chem 2006; 14: 2606-2612. (Pubitemid 43343648)
30. Modarai M et al. Metabolomic profiling of liquid Echinacea medicinal products with in vitro inhibitory effects on Cytochrome P450 3A4 (CYP3A4). Planta Med 2010; 76: 378-385.
31. Kleiner HE et al. Effects of naturally occurring coumarins on hepatic drug metabolizing enzymes in mice. Toxicol Appl Pharmacol 2008; 232: 337-350.
32. Zhou C et al. The dietary isothiocyanante sulforaphane is an antagonist of the human steroid and xeniobiotic nuclear receptor. Mol Pharmacol 2006; 71: 220-228.
33. Loew D et al. Stabilität und Biopharmazeutische Qualität. Voraussetzung für Bioverfügbarkeit und Wirksamkeit von Harpagophytum procumbens. In: Loewe D, Rietbrock N, eds. Phytopharmaka II- Forschung Und Klinische Anwendung. Darmstadt: Steinkopf-Verlag, 1996: 83-93.
34. Heinrich M et al. Herbal extracts used for upper respiratory tract infections: are there clinically relevant interactions with the Cytochrome P450 enzyme system? Planta Med 2008; 74: 657-660. (Pubitemid 351846780)